21st Century opportunities are affecting the entire drug development pipeline, and in this Executive Retreat we will focus upon the changing landscape for partnerships between sponsors and the key services that make their progress possible.
As the data revolution is affecting all aspects of early and translational studies, we'll explore the fresh terrain and new stumbling blocks these technologies unearth.
Global External Research Lead
President, Board of Directors
BioPharma Research Council
By bringing together thought leaders who are expert in both historic and emerging models of outsourcing early studies, we provide an opportunity to address common challenges in a precompetitive atmosphere.
Today's successful outsourcing partnerships must be based upon trust, mutual respect, clear lines of communication and deeply held responsibility. By sharing this intensive and interactive process, delegates will be better prepared for confronting opportunities suggested within their own companies, departments, and communities.
Wednesday, March 25, 6:00-9:00 pm
Registration and Opening Reception. During this time we'll gather informally, with One-on-One conversations organized in short segments.
Thursday, March 26, 8:00 am-5:00 pm, then 6:30-9:00 pm
A full day of keynotes, speakers and panelists, followed by a very special wine tasting hosted at Princeton University.
Friday, March 27, 9:00 am-2:00 pm
Subject-led Roundtables, Reporting Out regarding issues discussed.
Just outside Princeton, NJ, the Chauncey Hotel and Conference Center is the perfect setting for this Executive Retreat.
(subject to change)
Nintai Partners is a group of industry leaders with broad experience in biopharma, healthcare data and informatics. The group’s expertise includes pharmaceuticals research & development informatics, hospital electronic health records (EHR), clinical research data, and patient outcome research.
Managing Partner Tom Macpherson has worked in the healthcare informatics market for the past twenty years. His particular interest is in the growing integration of clinical and non-clinical data and its increasing benefits in organizational, clinical, and patient outcomes. As a cancer survivor, it has been with great personal interest watching the revolution and advances in health care over the past decade.
Mr. Macpherson received his undergraduate and graduate degrees from Harvard University. Prior to founding Nintai Partners, he was founder and COO of Mount Vernon Strategies, a boutique management consulting firm based in Boston. The company specialized in strategic development and private equity placement for growing businesses.
He serves on the boards of the Hayashi Foundation and the Robert F. Kennedy Center for Justice and Human Rights Leadership Council. He also serves on the Harvard Medical School Tech Advisory Board and the McKesson Technology Working Group. Mr. Macpherson spends a considerable amount of time in Asia and speaks Japanese.
Dr. Karam has 21 years experience in both outsourcing and internal portfolio management. He has built, developed and directed a broad external research biology portfolio at Pfizer with global reach and impact in support of biological & small molecule drug research.
At Pfizer and partner sites, Dr. Karam has developed and implemented strategies, best practices and guidelines, managing both internal & external portfolios and resources in support of global discovery.
His current portfolio supports globally all preclinical and early clinical areas of drug discovery for exploratory lead identification and development: Assay, Structure, Safety, Biomarker, Biologics, Biocatalysis, ADME, clinical toxicology, etc. In his role he aligns functions globally with Project teams, Scientists, Procurement, RI, Legal, Finance, and Strategic Alliances and has identified, setup best practices and engaged >225 CRO partners throughout the industry.
He has organized several Best Practices in Outsourcing meetings in collaboration with PlanetConnect and the BioPharma Research Council, and delivered keynote presentations throughout the US and internationally at various academic and industry symposia.
Dr. Karam is a graduate of the American University of Beirut and received his Ph.D. in Biochemistry and Genetics at Iowa State University. Prior to joining Pfizer he was a Research Fellow at Yale University School of Medicine.
Ronnye Schreiber is a cofounder & President of the BioPharma Research Council and serves as Board President. She is also cofounder of PlanetConnect Inc, a provider of confidential services to biopharmaceutical companies.
Her career began as a researcher focusing on biochemistry and immunology, developing immunoassays for oncology and cardiovascular therapeutic areas. She held positions at Dana-Farber Cancer Institute, Arthur D. Little, Rutgers Medical School and Ortho Diagnostics (now Ortho-Clinical Diagnostics) and has co-authored and published papers on this work.
At AT&T/Bell Labs, and Lucent, she developed marketing within the Broadband Multimedia Networking organization. She managed multimedia distance learning and information access product development, and provided information assessments for the Govt. of Manitoba, universities, Disney and other Fortune 500 companies. Within Lucent's Bell Laboratories, she directed the marketing, helpline and internal training teams for the Global Library Network.
Prior to co-founding PlanetConnect in 1996, Ms. Schreiber was Director, Conference Planning for Megasoft, where she managed custom, Internet-focused conferences for AT&T, Lucent and Johnson & Johnson.
She has a Master’s Degree from Rutgers University School of Library and Information Studies and a B.A. in Bacteriology from Douglass College of Rutgers University. She is a lifetime member of Beta Phi Mu and has served on the Advisory Board for Institute for Women's Leadership, Douglass College.